BioSpace

Delix raises $100M to advance at-home psychedelic without hallucinogenic effects

The series C raise, co-led by Johnson & Johnson’s venture capital arm, will help Delix Therapeutics push its novel psychedelic asset into mid-stage development for major depressive disorder.

By BioSpace

1 min read
Delix raises $100M to advance at-home psychedelic without hallucinogenic effects
AI-generated illustration

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights